Breast cancer risk assessment for women under 50 is being put under the microscope in a new UK study that examines not only which information matters most, but also how women want risk prediction to work in practice. Published in the British Journal of Cancer, the research by Dennison, Valasaki, Wright and colleagues combines a national survey with a discrete choice experiment, a method used to measure how people weigh competing benefits, burdens and uncertainties when choosing between realistic options.
The study addresses a fast-changing area of cancer prevention. Breast cancer is often associated with older age, yet younger women can also face substantially elevated risk because of inherited genetic variants, a strong family history, previous breast conditions or other biological and reproductive factors. For women below the routine screening age, the central question is more complex than whether they are “at risk” or “not at risk.” It is how much risk they face, how confidently that risk can be estimated, and what actions should follow from the result.
Traditional risk assessment has relied heavily on factors such as age, family history and previous diagnoses. Modern approaches can add information from genetic testing, including rare high-impact variants in genes such as BRCA1 and BRCA2, as well as polygenic risk scores. These scores combine the effects of many common genetic variants, each contributing a small change in susceptibility. Other models may also incorporate breast density, hormonal history, body characteristics and lifestyle factors. The challenge is that a more detailed model is not automatically a more useful one if the information is difficult to understand or does not lead to an acceptable clinical option.
That is why the researchers used a discrete choice experiment. In this type of study, participants are shown a series of hypothetical choices that differ across several attributes, such as the possible accuracy of an assessment, the type of information required, the time involved, the implications for screening or prevention, and the uncertainty surrounding the result. By analysing the choices statistically, researchers can estimate the relative importance participants assign to each attribute. The method can reveal priorities that are not always visible when people are simply asked to rank a list of preferences.
The survey component provides a wider picture of how women under 50 view breast cancer risk assessment, while the choice experiment probes the trade-offs behind those views. A participant might value a more precise estimate but be concerned about genetic testing, data privacy, follow-up appointments or the emotional effect of being labelled high risk. Another might prefer a simpler assessment that can be completed quickly, even if it produces a broader range of possible risk. These tensions are central to the design of any risk service intended for large populations rather than only specialist clinics.
Risk communication is particularly important when absolute risks are presented. A percentage can sound either alarming or reassuring depending on how it is framed, the time period it covers and the average risk used for comparison. A lifetime risk is not the same as a five-year risk, and a relative increase does not directly describe an individual’s probability of developing cancer. Technical models also produce confidence intervals, meaning that an estimate is better understood as a range rather than a perfectly precise personal forecast. For younger women, whose underlying short-term risk may be lower but whose lifetime exposure is longer, these distinctions can strongly influence decisions.
The findings are relevant to the possible expansion of risk-stratified breast screening in the UK. Instead of offering identical screening schedules to everyone in a particular age group, risk-stratified programmes aim to match surveillance intensity to an individual’s estimated risk. Women at higher risk might be offered earlier or more frequent imaging, magnetic resonance imaging, preventive medicines or referral to genetics services. Women at lower risk could potentially avoid unnecessary investigations. However, such systems must be carefully evaluated because false-positive results can lead to anxiety, additional imaging and biopsies, while false reassurance can delay attention to symptoms.
The researchers’ focus on women under 50 also highlights a population that can be overlooked by age-based screening policies. Younger women may be balancing work, childcare, pregnancy planning and concerns about inherited risk within their families. Breast tissue is often denser before menopause, which can make mammographic interpretation more difficult, and symptoms may be mistakenly attributed to benign changes. A risk assessment pathway designed around the realities of younger women therefore needs to be clinically credible, accessible and sensitive to the consequences of recommendations that may extend over decades.
The study does not suggest that a single test will solve the problem of breast cancer prevention. Rather, it points toward a more patient-centred model in which technical performance and personal priorities are considered together. A risk tool may be scientifically powerful, but its public-health value depends on whether women trust it, understand its limitations and can access appropriate follow-up. The research offers evidence for policymakers and clinicians deciding which features should be prioritised as the UK develops future approaches to earlier detection and personalised prevention.
As genetic and statistical technologies become more widely available, the debate over breast cancer risk assessment is moving beyond what can be measured to what should be offered. The new study places women’s preferences at the centre of that discussion. Its message is likely to resonate far beyond the clinic: better prediction is not simply a matter of collecting more data, but of turning complex information into decisions that are accurate, understandable and genuinely useful for the people whose lives may be changed by the result.
Subject of Research: Breast cancer risk assessment priorities among women in the UK under age 50
Article Title: Priorities for breast cancer risk assessment in UK women under age 50: a survey and discrete choice experiment
Article References: Dennison, R.A., Valasaki, M., Wright, S. et al. Priorities for breast cancer risk assessment in UK women under age 50: a survey and discrete choice experiment. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03546-3
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41416-026-03546-3
Keywords: breast cancer, risk assessment, women under 50, personalised screening, genetic risk, polygenic risk scores, discrete choice experiment, UK healthcare, cancer prevention, patient preferences
Tags: Breast cancer risk assessment for women under 50challenges of risk estimation in younger womendecision-making in breast cancer screening and preventiondiscrete choice experiments in health researchearly detection strategies for young womenevolving methods in breast cancer riskfamily history and reproductive factors in breast cancer riskgenetic testing and inherited cancer riskimpact of genetic variants like BRCA1 on breast cancer riskimproving risk prediction models for women under 50patient preferences in cancer risk communicationpersonalized cancer prevention approaches
